Could hepatitis c kidneys solve the organ shortage?

NCT ID NCT04075916

Completed Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether kidneys from deceased donors with hepatitis C can be safely transplanted into people without hepatitis C. All 201 participants received antiviral medication after transplant to clear any infection. The goal was to see if this approach could safely increase the number of available kidneys and reduce waiting times for transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sofosbuvir/velpatasvir (Epclusa)
What this could lead to: If successful, this could expand the donor kidney pool, reducing wait times for people with end-stage kidney disease.
What could go wrong: This is a phase 2 trial with 201 participants, so results may not apply to everyone. There is a risk of hepatitis C transmission or other complications despite antiviral treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE

Contacts and locations

Show contact details

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Jackson Memorial Hospital/University of Miami

Miami, Florida, 33136, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
New York Presbyterian Hospital/Columbia University

New York, New York, 10032, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Florida

Gainesville, Florida, 32608, United States
Vanderbilt University

Nashville, Tennessee, 37235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.